Latest news from 2023 AACC Annual Scientific Meeting Press Program on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/revolutionizing-liquid-biopsy-zymo-research-and-opentrons-partner-to-automate-novel-cell-free-dna-isolation-chemistry/?sc=rsin /articles/revolutionizing-liquid-biopsy-zymo-research-and-opentrons-partner-to-automate-novel-cell-free-dna-isolation-chemistry/?sc=rsin Wed, 26 Jul 2023 13:10:22 EST Zymo Research Corp, a leading provider of life science technologies, has partnered with Opentrons Labworks, Inc., a leader in lab automation, to revolutionize cell-free DNA isolation and analysis. 2023 AACC Annual Scientific Meeting Press Program /articles/first-ever-point-of-care-instrument-to-test-for-fentanyl-receives-fda-clearance/?sc=rsin /articles/first-ever-point-of-care-instrument-to-test-for-fentanyl-receives-fda-clearance/?sc=rsin Wed, 26 Jul 2023 08:15:29 EST Shenzhen Superbio Technology Co., LTD. (Superbio) has received clearance from the US Food and Drug Administration (FDA) on the first ever point-of-care instrument intended for qualitative detection of fentanyl in human urine and has fully released authorization to Bioeasy USA, Inc.(Bioeasy) of this product in the United States of America. 2023 AACC Annual Scientific Meeting Press Program /articles/actiphage-tb-awarded-us-patent-grant-for-diagnostic-kit/?sc=rsin /articles/actiphage-tb-awarded-us-patent-grant-for-diagnostic-kit/?sc=rsin Tue, 25 Jul 2023 22:50:12 EST PBD Biotech developers of Actiphage TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit. The company is exhibiting in the AACC Clinical Lab Expo on booth #4578. 2023 AACC Annual Scientific Meeting Press Program /articles/general-biologicals-corporation-debuts-award-winning-brand-at-scientific-clinical-lab-expo/?sc=rsin /articles/general-biologicals-corporation-debuts-award-winning-brand-at-scientific-clinical-lab-expo/?sc=rsin Tue, 25 Jul 2023 08:00:29 EST Taiwanese IVD (In-Vitro Diagnostic) manufacturer General Biologicals Corporation (GBC) today unveiled two CellBio(tm) circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, being held July 23-27 in Anaheim, California. 2023 AACC Annual Scientific Meeting Press Program /articles/pre-analytic-innovations-from-sarstedt-at-aacc-annual-scientific-meeting-clinical-lab-expo/?sc=rsin /articles/pre-analytic-innovations-from-sarstedt-at-aacc-annual-scientific-meeting-clinical-lab-expo/?sc=rsin Tue, 25 Jul 2023 07:50:55 EST As a leader in pre-analytic innovation, SARSTEDT provides 360 solutions for improving specimen quality, reducing turnaround time, and automating labs of all sizes with customizable modular systems. 2023 AACC Annual Scientific Meeting Press Program /articles/quality-improves-efficiencies-with-a2la-s-45-years-of-experience/?sc=rsin /articles/quality-improves-efficiencies-with-a2la-s-45-years-of-experience/?sc=rsin Mon, 24 Jul 2023 15:05:10 EST Quality Improves Efficiencies with A2LA's 45 Years of Experience 2023 AACC Annual Scientific Meeting Press Program /articles/new-day-diagnostics-llc-reinforces-commitment-to-early-cancer-intervention-with-its-intention-to-acquire-the-assets-of-epigenomics-ag/?sc=rsin /articles/new-day-diagnostics-llc-reinforces-commitment-to-early-cancer-intervention-with-its-intention-to-acquire-the-assets-of-epigenomics-ag/?sc=rsin Mon, 24 Jul 2023 14:05:39 EST New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer. 2023 AACC Annual Scientific Meeting Press Program /articles/at-an-event-in-california-a-brazilian-health-tech-company-presented-its-exclusive-technology-for-blood-tests-with-ai-delivering-results-within-30-minutes/?sc=rsin /articles/at-an-event-in-california-a-brazilian-health-tech-company-presented-its-exclusive-technology-for-blood-tests-with-ai-delivering-results-within-30-minutes/?sc=rsin Fri, 21 Jul 2023 16:20:00 EST During the AACC - Annual Scientific Meeting & Clinical Lab Expo, held in Anaheim, California (USA) from July 23rd to 27th, the Brazilian health tech company Hilab, specializing in clinical analysis tests, participated in the congress alongside ABIMO - Brazilian Association of Medical Devices Industry. 2023 AACC Annual Scientific Meeting Press Program /articles/introducing-peakv-the-world-s-first-large-sample-volume-open-assay-super-fast-ultra-sensitive-and-sample-to-answer-pcr-instrument/?sc=rsin /articles/introducing-peakv-the-world-s-first-large-sample-volume-open-assay-super-fast-ultra-sensitive-and-sample-to-answer-pcr-instrument/?sc=rsin Fri, 21 Jul 2023 08:50:45 EST Developed by OnsiteGene Inc. and sponsored by the NIH RADx initiative, PeakV is a sample-to-answer instrument that transforms PCR testing. 2023 AACC Annual Scientific Meeting Press Program /articles/co-diagnostics-inc-to-host-booth-and-discuss-recent-grant-awards-at-aacc-2023-in-anaheim-ca/?sc=rsin /articles/co-diagnostics-inc-to-host-booth-and-discuss-recent-grant-awards-at-aacc-2023-in-anaheim-ca/?sc=rsin Thu, 20 Jul 2023 17:20:40 EST Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the American Association for Clinical Chemistry (AACC) annual meeting and expo held July 23-27, 2023 in Anaheim, CA. 2023 AACC Annual Scientific Meeting Press Program /articles/massachusetts-general-hospital-researchers-and-prevencio-announce-the-power-of-artificial-intelligence-hart-platform-for-medical-diagnostic-test-development/?sc=rsin /articles/massachusetts-general-hospital-researchers-and-prevencio-announce-the-power-of-artificial-intelligence-hart-platform-for-medical-diagnostic-test-development/?sc=rsin Thu, 20 Jul 2023 08:05:10 EST Prevencio, Inc. today announces the culminative presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART(r) blood tests are highly accurate in a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease. 2023 AACC Annual Scientific Meeting Press Program